




sFig.1 Risk of bias summary: each risk of bias item for each included study.



sFig.2 Forest plot of all-cause death based on fostamatinib versus placebo.




sFig.3 Forest plot of MACE based on fostamatinib versus placebo.




sFig.4 Forest plot of MACE based on fostamatinib 100mg bid versus fostamatinib 150mg qd.

	Fostama	atinib	Place	bo		Peto Odds Ratio		Peto O	dds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% C	1	Peto, Fix	ced, 95% CI	
NCT00326339	0	142	0	47		Not estimable	9			
NCT00665626	0	146	0	73		Not estimable	9			
NCT00665925	1	304	1	153	26.1%	0.48 [0.03, 8.99]	-		
NCT01197521	1	614	0	304	13.0%	4.46 [0.07, 287.06]]	(50 (50	1	- 88
NCT01197534	1	606	0	302	13.0%	4.47 [0.07, 286.68]	18		- 88
NCT01197755	1	213	1	109	26.2%	0.49 [0.03, 9.11]	1		30	
NCT01264770	2	159	0	52	21.7%	3.79 [0.15, 95.30]]			-88
NCT01563978	0	68	0	67		Not estimable	9			
NCT01569074	0	130	0	33		Not estimable	9			
NCT02092961	0	33	0	29		Not estimable	e			
Total (95% CI)		2415		1169	100.0%	1.34 [0.30, 6.03]]	4		
Total events	6		2							
Heterogeneity: Chi ² =	1.98, df=	4 (P = 0)	$.74); I^2 =$	0%			+		1 10	
Test for overall effect	Z = 0.39 (1	P = 0.70)				0.002 Favours F	0.1 ostamatinit	1 10 Favours Pla	500 cebo

sFig.5 Forest plot of ischaemic heart disease based on fostamatinib versus placebo.




sFig.6 Forest plot of ischaemic heart disease based on fostamatinib 100mg bid versus fostamatinib 150mg qd.




sFig.7 Forest plot of stroke based on fostamatinib versus placebo.

	Fostamatinib 10	Omg bid	Fostamatinib 15	0mg qd		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
NCT00326339	0	49	0	47		Not estimable	
NCT00665925	0	152	0	152		Not estimable	
NCT00831922	0	22	0	18		Not estimable	
NCT01197521	0	614	1	304	57.2%	0.05 [0.00, 3.14]	1
NCT01197534	0	610	0	298		Not estimable	
NCT01197755	0	105	0	108		Not estimable	
NCT01242514	1	1343	0	357	42.8%	3.55 [0.03, 436.08]	
NCT01264770	0	81	0	73		Not estimable	
NCT01569074	0	31	0	33		Not estimable	
Total (95% CI)		3007		1390	100.0%	0.31 [0.01, 7.13]	
Total events	1		1				
Heterogeneity: Chi ² =	1.74, df = 1 (P = 0.	19); $I^2 = 43$	3%				t t t t t t t t t t t t t t t t t t t
Test for overall effect	Z = 0.74 (P = 0.46))					0.001 0.1 1 10 1000 Fostamatinib 100mg bid Fostamatinib 150mg qd


sFig.8 Forest plot of stroke based on fostamatinib 100mg bid versus fostamatinib 150mg qd.



sFig.9 Forest plot of pulmonary heart disease and disease of pulmonary circulation based on fostamatinib versus placebo.



sFig.10 Forest plot of pulmonary heart disease and disease of pulmonary circulation based on fostamatinib 100mg bid versus fostamatinib 150mg qd.




sFig.11 Forest plot of other forms of heart disease based on fostamatinib versus placebo.

	Fostamatinib 10	Omg bid	Fostamatinib 15	0mg qd		Peto Odds Ratio	Peto Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	Peto, Fixed, 95% CI	Peto, Fixed, 95% CI
NCT00326339	0	49	0	47		Not estimable	
NCT00665925	0	152	0	152		Not estimable	
NCT00831922	0	22	0	18		Not estimable	
NCT01197521	1	614	5	304	30.6%	0.10 [0.02, 0.56]	- I
NCT01197534	6	610	2	298	40.6%	1.43 [0.32, 6.29]	
NCT01197755	0	105	1	108	5.8%	0.14 [0.00, 7.02]	
NCT01242514	6	1343	0	357	23.0%	3.56 [0.50, 25.46]	- •
NCT01264770	0	81	0	73		Not estimable	
NCT01569074	0	31	0	33		Not estimable	2
Total (95% CI)		3007		1390	100.0%	0.69 [0.27, 1.76]	•
Total events	13		8				
Heterogeneity: Chi ² =	9.06, df = 3 (P = 0.	03); I ² = 67	%				- t
Test for overall effect	Z= 0.78 (P = 0.44)	, ,					0.002 0.1 1 10 500 Fostamatinib 100mg bid Fostamatinib 150mg qd


sFig.12 Forest plot of other forms of heart disease based on fostamatinib 100mg bid versus fostamatinib 150mg qd.

	Fostama	atinib	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 4 weeks							
NCT01563978	3	68	1	67	1.5%	2.96 [0.32, 27.71]	
Subtotal (95% CI)		68		67	1.5%	2.96 [0.32, 27.71]	
Total events	3		1				
Heterogeneity: Not ap	oplicable						
Test for overall effect	Z = 0.95 (P = 0.34)				
1.1.2 12 weeks							
NCT00326339	5	142	0	47	1.1%	3.69 [0.21, 65.55]	
NCT00665626	19	146	3	73	5.8%	3.17 [0.97, 10.36]	,
NCT01569074	23	130	2	33	4.6%	2.92 [0.72, 11.76]	
Subtotal (95% CI)		418		153	11.4%	3.12 [1.32, 7.38]	•
Total events	47		5				
Heterogeneity: Chi ² =	0.02, df=	2(P = 0)	.99); 2=	0%			
Test for overall effect	Z= 2.59 (I	P = 0.01	0)				
1.1.3 24 weeks							
NCT00665925	39	304	7	153	13.4%	2.80 [1.28, 6.12]	
NCT01197755	29	213	9	109	17.2%	1.65 [0.81, 3.36]	 •
NCT01264770	15	159	0	52		10.27 [0.63, 168.69]	
NCT02092961	4	33	1	29	1.5%	3.52 [0.42, 29.69]	
Subtotal (95% CI)		709		343	33.2%	2.48 [1.51, 4.10]	•
Total events	87		17				
Heterogeneity: Chi ² =	2.46, df=	3(P = 0)	.48); 2=	0%			
Test for overall effect	Z = 3.56 (1	P = 0.00	104)				
1.1.4 52 weeks							
NCT01197521	148	614	12	304	23.1%	6.11 [3.45, 10.82]	
NCT01197534	123	606	16	302	30.8%	3.83 [2.32, 6.33]	
Subtotal (95% CI)		1220		606	53.9%	4.81 [3.30, 7.01]	•
Total events	271		28			\$7 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
Heterogeneity: Chi ² =	1.46. df=	1 (P = 0)	.23); 2=	31%			
Test for overall effect	Z= 8.17 (P < 0.00	1001)				
Total (95% CI)		2415		1169	100.0%	3.82 [2.88, 5.05]	•
Total events	408		51				
Heterogeneity: Chi ² =	11 12 1 TO TO TO THE	9 (P = 0		3%			
Test for overall effect			0.530000	- /-		ė.	_0.01 _ 0.1 _ 1 10 _ 100
Test for subaroup dif				/D = 0	24) 12 - 2	22.40	Favours Fostamatinib Favours Placebo


sFig.13 Forest plot of hypertension based on fostamatinib versus placebo.



sFig.14 Forest plot of hypertension based on fostamatinib 100mg bid versus fostamatinib 150mg qd.



sFig.15 Forest plot of hypertension based on fostamatinib 100mg bid versus fostamatinib 100mg qd.



sFig.16 Forest plot of hypertension based on fostamatinib versus adamumab.